Actively Recruiting
Evaluating Low-Intensity Chemotherapy Combined with Olverembatinib and Venetoclax in Adults with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Led by Institute of Hematology & Blood Diseases Hospital, China · Updated on 2026-07-23
110
Participants Needed
1
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effectiveness and safety of combining reduced-intensity chemotherapy with targeted therapy and immunotherapy in adults newly diagnosed with Philadelphia chromosome-positive acute lymphoblastic leukemia Ph ALL. The study is open-label and prospective, involving two parts one randomized comparison of adding venetoclax to olverembatinib and chemotherapy, and another exploring inotuzumab ozogamicin with TKI and chemotherapy as consolidation for patients not receiving blinatumomab. The study focuses on molecular response rates and event-free survival. Participants receive a backbone of low-intensity chemotherapy combined with olverembatinib, a third-generation tyrosine kinase inhibitor, with schedules including induction, consolidation, and maintenance phases lasting up to several years. The experimental arm adds venetoclax during initial treatment cycles. Optional add-ons include blinatumomab or inotuzumab ozogamicin starting from cycle 4, with allogeneic stem cell transplantation as an option for patients with residual disease after treatment cycles. Throughout the study, participants undergo regular assessments including molecular testing for BCR-ABL levels, event-free survival tracking, and monitoring for adverse effects such as cardiovascular events and veno-occlusive disease. Follow-up extends up to five years for survival and relapse outcomes. The total participation time varies depending on treatment phase and responses, with detailed evaluations during treatment cycles and long-term monitoring afterwards.
CONDITIONS
Brief Title
Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL
Research Team
H
Hui Wei, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here